Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET
Access the event here
THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company's first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available on the Events page under the Investors section of the Company's website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
Investor and Media Contact
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV season. The drug will be marketed under the brand name Enflonsia. The FDA's decision came a day ahead of the previously announced target date of June 10, 2025. The approval is based on data from the pivotal phase IIb/III CLEVER study, which showed that treatment with a single dose of Enflonsia significantly reduced the incidence of RSV disease and hospitalization in healthy preterm and full-term infants. Merck plans to launch Enflonsia in the United States ahead of the upcoming 2025-26 RSV season and expects ordering for the shots to start next month. Per a Reuters article, Merck will price the antibody at $556 per dose. Merck's Stock Performance Year to date, Merck's shares have lost 20% compared with the industry 's 1% decline. Other RSV Antibodies/Vaccines Available in the Market Once commercially launched, Merck's Enflonsia will face stiff competition from AstraZeneca AZN / Sanofi 's SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023. This AstraZeneca-Sanofi antibody achieved blockbuster status in its first full-year sales in 2024. Coincidentally, on the same day Enflonsia received approval, Sanofi revealed an aggressive effort to increase the supply of the AstraZeneca-partnered Beyfortus, including a plan to start shipping the antibody early in the third quarter of 2025. While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants is Pfizer 's PFE Abrysvo. Unlike Beyfortus and Enflonsia, which can be administered directly, the Pfizer vaccine protects infants through maternal immunization. Most of the marketed RSV vaccines, including Pfizer's, are approved for use in older adults aged 60 years and above. MRK's Cholesterol Drug Meets Goal in Two Late-Stage Studies In a separate press release, Merck announced topline data from two phase III studies, CORALreef HeFH and CORALreef AddOn, which evaluated their investigational oral PCSK9 inhibitor, enlicitide decanoate, in adults with hyperlipidemia who had been previously treated with a statin. Both studies met their primary and key secondary endpoints, showing statistically significant and clinically meaningful greater reductions in low-density lipoprotein cholesterol (LDL-C) after treatment with enlicitide. While the CORALreef HeFH evaluated the drug against a placebo, the CORALreef AddOn assessed the drug against other oral non-statin therapies. MRK's Zacks Rank Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
21 minutes ago
- Globe and Mail
QCOM Gains Traction in Automotive: Will It Deliver Sustainable Growth?
Qualcomm Incorporated QCOM has been witnessing solid momentum in the automotive segment over the past few quarters. During the second quarter of 2025, the company reported staggering 59% year-over-year growth in this segment. It boasts a worldwide client base that includes leading automakers and technology companies like General Motors, BMW, Mercedes-Benz, Renault Group, Royal Enfield, Volvo, Google and more. Over the past few years, Qualcomm has taken an approach of continuous innovation with strategic acquisitions to expand into the automotive market. Since the acquisition of Veneer, Inc., the company has steadily gained a strong foothold in the emerging market of driver-assistance technology. The Arriver business of Veoneer operates the dedicated software unit focused on sensor perception and drive policy, including a full stack of features and functions. With this buyout, Qualcomm has integrated Arriver's Computer Vision, Drive Policy and Driver Assistance assets into its ADAS (Advanced Driver Assistance System) portfolio. It has allowed QCOM to deliver an open and competitive platform for automakers to better compete with rivals within the self-driving vehicle market. The company recently acquired Autotalks, an industry leader in direct vehicle-to-everything communication technology. Integration of Autotalks' robust portfolio of automotive-qualified global V2X solutions will facilitate the development of leading-edge, reliable solutions to enhance road safety and optimize traffic efficiency. Growing demand for the company's Snapdragon Digital Chassis product portfolio, which includes telematics and connectivity platforms, digital cockpit and C-V2X solutions, is expected to drive growth in automotive in the near term. In the second quarter, Qualcomm secured 30 new designs, including five ADAS programs and designs from Chinese automakers such as Nio, Zeekr, Great Wall, Dongfeng and more. Per our estimate, the company is expected to generate $3.7 billion in revenues from the automotive segment, indicating 27.3% year-over-year growth. How Are Competitors Faring? In the automotive segment, the company faces competition from the NVIDIA Corporation NVDA and Intel Corporation INTC. NVIDIA DRIVE solutions include a comprehensive stack of hardware and software tools designed to support autonomous vehicles. It is also swiftly working on V2X technology, specifically in AI-driven connectivity for autonomous vehicles. With a vast client base that includes Mercedes-Benz, Li Auto, General Motors, Toyota and several other prominent automakers, NVIDIA has gained solid market traction in the AI-driven autonomous driving space. Intel's Mobileye has rapidly expanded in the autonomous car technology market. Mobileye's technologies related to cameras, in-car networking, sensor chips, roadway mapping, cloud software, machine learning and data management are gaining popularity among automakers. More than 70 million vehicles from BMW, Volkswagen, Ford and Nissan use Intel's Mobileye for driver assistance. However, with the integration of advanced V2X and a broader portfolio of digital cockpit, infotainment and connectivity, Qualcomm is expected to maintain its competitive edge in the automotive vertical. QCOM's Price Performance, Valuation and Estimates QCOM shares have declined 25.5% over the past year against the industry 's growth of 18.1%. Image Source: Zacks Investment Research Going by the price/earnings ratio, the company's shares currently trade at 12.87 forward earnings, lower than 30.31 for the industry and the stock's mean of 17.79. It carries a Value Score of A. Image Source: Zacks Investment Research Earnings estimates for 2025 have decreased 0.17% to $11.8 per share over the past 60 days, while the same for 2026 have decreased 3.18% to $12.19. Qualcomm stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report QUALCOMM Incorporated (QCOM): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
Globe and Mail
21 minutes ago
- Globe and Mail
MU's HBM Revenues Surpass $1 Billion: Will the Momentum Persist?
Micron Technology 's MU high bandwidth memory (HBM) chips are experiencing robust traction due to their growing use in high-performance computing, hyperscalers and artificial intelligence data centers. The high demand for these chips has led to Micron's HBM revenues crossing $1 billion in the second quarter of fiscal 2025, marking a major milestone. Since Micron's HBM3E and HBM3E-12H variants offer significant power reduction in comparison to its competitors while also delivering higher memory capacity, customers have already placed a large demand for these products, resulting in Micron being fully sold out of its HBM supply for calendar 2025. The HBMs developed by Micron have a total addressable market estimate of more than $35 billion for the calendar year 2025. Now the company is focusing on HBM delivery agreements for 2026. It is worth noting that the largest AI-chip manufacturer, NVIDIA NVDA, announced in January 2025 that Micron is a key supplier for its GeForce RTX 50 Blackwell GPUs, solidifying Micron's positioning in the HBM market. NVIDIA has installed Micron's HBM3E 8H chips inside the NVIDIA GB200 system and HBM3E 12H chips in NVIDIA GB300. To top it all off, Micron is developing the next generation of high bandwidth memory, HBM4, which will increase the bandwidth by more than 60% compared to HBM3E. The company will ramp the production volume of HBM4 in 2026. With Micron experiencing a sequential surge of 50% in HBM revenues in the second quarter of fiscal 2025, and considering its future plans, it is quite evident that momentum in HBMs will persist. Micron anticipates third-quarter fiscal 2025 revenues of $8.80 billion (+/-$200 million). The Zacks Consensus Estimates for third-quarter fiscal 2025 is pegged at $8.81 billion, indicating year-over-year growth of 29.33%. How Competitors Fare Against Micron The global HBM market is highly consolidated, with a handful of players in this space. Companies, including SK hynix, TSMC TSM and Samsung, exist in this space. However, not all of them compete directly against Micron. While SK Hynix and Samsung develop their own HBM2E, HBM3, and HBM3E, TSMC develops HBM packages based on SK Hynix's HBMs. In 2024, SK hynix and TSMC collaborated to collectively develop HBM4 and next-generation packaging technology. This collaboration has led SK hynix to adopt TSMC's foundry process to develop its HBM4, showcased for the first time in April 2025. Since the HBM space has a few capable players and huge growth opportunities, this provides a strong growth opportunity for Micron. Micron's Price Performance, Valuation and Estimates Shares of MU have gained 31.8% year to date compared with the Zacks Computer - Integrated Systems industry's growth of 15.1%. Image Source: Zacks Investment Research From a valuation standpoint, MU trades at a forward price-to-sales ratio of 2.84X, lower than the industry's average of 3.53X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for MU's fiscal 2025 earnings implies year-over-year growth of 433%, while the 2026 earnings estimate implies growth of 55.87%. The estimates for fiscal 2025 earnings have been revised upward, while the 2026 earnings have been revised downward in the past 60 days. MU currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Micron Technology, Inc. (MU): Free Stock Analysis Report
